Literature DB >> 10474267

[Inhibition of tumor neo-angiogenesis and induction of apoptosis as properties of docetaxel (taxotere)].

R Schimming1, N R Hunter, K A Mason, L Milas.   

Abstract

Paclitaxel and docetaxel are potent drugs that are effective in the treatment of malignant tumors. The cytotoxic action of these drugs is not fully understood, but it appears to be mediated mainly through mitotic arrest and subsequent apoptosis. Because no information is available on the antiangiogenesis action of docetaxel, the investigations were performed to determine whether inhibition of neoangiogenesis plays a role in docetaxel's antitumor efficacy. Four different mouse tumors, two squamous cell carcinomas (SCC-IV; SCC-VII) and two adenocarcinomas (MCA-4; MCA-29) were assayed for angiogenic activity using the in vivo i.c. angiogenesis assay. Tumor cells (5 x 10(5)) were injected i.c. into the skin flap over the abdominal wall, and the number of new blood vessels at the tumor cell injection site was determined 2, 4, 6, 8, 10 and 12 days later. The mice were treated with docetaxel (Taxotere--31.3 mg/kg i.v.) 1 or 4 days after tumor cell injection. The number of new blood vessels increased with time. Docetaxel reduced the number of newly formed blood vessels in MCAs, but not in SCCs. The reduction was associated with slower tumor growth. In a separate set of experiments we observed that docetaxel's inhibitory effect on the two MCAs was histologically associated with massive tumor cell destruction by means of both apoptosis and necrosis. This was not observed for the two SCCs. Since no reduction in blood vessels occurred in tumors unresponsive to docetaxel, the inhibition of neoangiogenesis in docetaxel-responsive tumors was likely the result of a decrease in angiogenic stimuli due to docetaxel's destruction of tumor cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10474267     DOI: 10.1007/s100060050132

Source DB:  PubMed          Journal:  Mund Kiefer Gesichtschir        ISSN: 1432-9417


  5 in total

Review 1.  Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy.

Authors:  L Vigano; A Locatelli; G Grasselli; L Gianni
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

2.  Inhibitory effects of docetaxel on expression of VEGF, bFGF and MMPs of LS174T cell.

Authors:  Xue-Liang Guo; Geng-Jin Lin; Hong Zhao; Yong Gao; Li-Ping Qian; San-Rong Xu; Li-Na Fu; Qing Xu; Jie-Jun Wang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

3.  A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer.

Authors:  Sheri K Dennison; Samuel A Jacobs; John W Wilson; Janell Seeger; Terrence P Cescon; Jane M Raymond; Charles E Geyer; Norman Wolmark; Sandra M Swain
Journal:  Invest New Drugs       Date:  2007-06-12       Impact factor: 3.850

4.  A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers.

Authors:  Joseph Baar; Paula Silverman; Janice Lyons; Pingfu Fu; Fadi Abdul-Karim; Nicholas Ziats; Jay Wasman; Paul Hartman; John Jesberger; Leda Dumadag; Erin Hohler; Rosemary Leeming; Robert Shenk; Helen Chen; Keith McCrae; Afshin Dowlati; Scot C Remick; Beth Overmoyer
Journal:  Clin Cancer Res       Date:  2009-05-05       Impact factor: 12.531

5.  IDN 5390: an oral taxane candidate for protracted treatment schedules.

Authors:  G Pratesi; D Laccabue; C Lanzi; G Cassinelli; R Supino; M Zucchetti; R Frapolli; M D'Incalci; E Bombardelli; P Morazzoni; A Riva; F Zunino
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.